为您找到相关结果约500个

你是不是要搜索 期刊抗体药物偶联物Polivy（polatuzumab vedotin） 点击跳转

More Flexibility in Preparation: Polivy (polatuzumab vedotin) now also available as 30-mg Vial

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq(POLIVY (R)) Antibody-Drug Conjugate in Sprague Dawley Rats

Polatuzumab Vedotin: First Global Approval

Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant

Polatuzumab Vedotin: a New Target for B Cell Malignancies

Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniques

Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma

Gastrointestinal Adverse Events Following Brentuximab Vedotin and Polatuzumab Vedotin Therapy

Molecular determinants of sensitivity to Polatuzumab-Vedotin

Excellent Interim Treatment Response with Polatuzumab Vedotin

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Polatuzumab Vedotin: First Global Approval (vol 79, pg 1467, 2019)

为您找到相关结果约500个

共500条页码: 1/34页15条/页